Balloon News

Belo Sun Mining Corp. is pleased to announce that it has acquired the material surface rights at its 100% owned Volta Grande gold project in Para State, Brazil.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy.

Shares of Boston Scientific Corporation ended the trading session lower by $0.12 or -1.89% from its previous close.

Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing.

NATICK, Mass., May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium Stent System in treating de novo coronary lesions in small coronary vessels.

Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epica Vascular Self-Expanding Stent System.

Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer /PRNewswire/ -- Boston Scientific Corporation announces that the SYNERGYTM Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent ... (more)

Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

A Natick-based Boston Scientific announced that it has introduced its new stent system in Europe, known as Innova.

The data showed a reduction in the risk of ischemic stroke by 75 percent in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin.

The fourth-generation drug-eluting stent is the newest product to reinforce our leading drug-eluting stent pipeline and our commitment to maintaining worldwide DES market leadership," said , M.D., global chief medical officer, Boston Scientific.

Boston Scientific Corp. 's Ingenio and Advantio pacemakers won U.S. approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 billion global market.

The pile of lawsuits is growing against Natick-based Boston Scientific and rival manufacturers over vaginal mesh inserts that were used to help with incontinence or a condition known as pelvic organ prolapse, the Patriot Ledger reports.

Natick-based Boston Scientific announced in March its intention to buy Cameron for $1.35 billion.